ArticleCancer immunology, immunotherapy : CII2019
Can benign lymphoid tissue changes in
Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- The value ofEuropean journal of nuclear medicine and molecular imaging · 2021Pooled it
- Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.BMC medicine · 2020Pooled it
- [European journal of nuclear medicine and molecular imaging · 2026Review
- Association between reactive cutaneous capillary endothelial proliferation and the efficacy of camrelizumab in esophageal cancer: a retrospective cohort study.Journal of thoracic disease · 2025Article
- Programmable Release of Chemotherapeutics from Ferrocene-Based Injectable Hydrogels Slows Melanoma Growth.Advanced healthcare materials · 2024Article
- Can physiologic colonic [European journal of nuclear medicine and molecular imaging · 2023Article
- Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy.European journal of nuclear medicine and molecular imaging · 2023Review
- Imaging assessment of toxicity related to immune checkpoint inhibitors.Frontiers in immunology · 2023Review
- Imaging glucose metabolism to reveal tumor progression.Frontiers in physiology · 2023Review
- Article
- Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [European journal of nuclear medicine and molecular imaging · 2022Article
- The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors.Frontiers in immunology · 2022Review
- Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.Frontiers in immunology · 2022Article
- Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [Journal of clinical medicine · 2021Review
- Assessment of early metabolic progression in melanoma patients under immunotherapy: anEJNMMI research · 2021Article
- Immune PET Imaging.Radiologic clinics of North America · 2021Review
- Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies.Cancer immunology, immunotherapy : CII · 2021Article
- Quantitative DynamicCancers · 2021Article
- FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.Seminars in nuclear medicine · 2020Review
- Impact of PET/CT for Assessing Response to Immunotherapy-A Clinical Perspective.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn association between immune-related adverse events (irAEs) caused by immunotherapeutic agents and the clinical benefit of immunotherapy has been suggested. We retrospectively evaluated by means of
methodsA total of 41 patients with unresectable metastatic melanoma underwent
resultsAccording to the BCR reference, 31 patients showed disease control (DC) and 10 patients showed progressive disease (PD). Mediastinal/hilar lymph node evaluation revealed that in total 4 patients in the interim or late PET/CT (10%) demonstrated a 'sarcoid-like lymphadenopathy' as response to treatment (LN-positive). All LN-positive patients responded to ipilimumab with DC. On the other hand, no significant differences between the DC and PD groups regarding both semi-quantitative and quantitative
conclusionBased on our findings, 10% patients in the interim or late PET/CT showed 'sarcoid-like lymphadenopathy' as response to treatment. All these patients showed disease control, implying a relation between the appearance of sarcoid-like lymphadenopathy and the clinical benefit of anti-CTLA-4 therapy. On the other hand, quantitative
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.